MSLN and familial pancreatic carcinoma: Taken together, our therapeutic strategy of combining MSLN‐targeted antibody with personalized neoantigen vaccine could provide a new perspective for improve therapeutic outcomes by efficiently relieving the immunosuppressive state of pancreatic cancer microenvironment.